Inflammopharmacology, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 28, 2024
Language: Английский
Cytokine & Growth Factor Reviews, Journal Year: 2024, Volume and Issue: 78, P. 105 - 119
Published: July 2, 2024
Language: Английский
Citations
20
Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102665 - 102665
Published: Jan. 1, 2025
Language: Английский
Citations
8
Ageing Research Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 102515 - 102515
Published: Sept. 1, 2024
Language: Английский
Citations
8
Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(1), P. 104 - 104
Published: Jan. 15, 2025
Cytokine-mediated inflammation is increasingly recognized for playing a vital role in the pathophysiology of wide range brain disorders, including neurodegenerative, psychiatric, and neurodevelopmental problems. Pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) cause neuroinflammation, alter function, accelerate disease development. Despite progress understanding these pathways, effective medicines targeting are still limited. Traditional anti-inflammatory immunomodulatory drugs peripheral inflammatory illnesses. Still, they face substantial hurdles when applied to central nervous system (CNS), blood-brain barrier (BBB) unwanted systemic effects. This review highlights developing treatment techniques modifying cytokine-driven focusing on advances that selectively target critical involved pathology. Novel approaches, cytokine-specific inhibitors, antibody-based therapeutics, gene- RNA-based interventions, sophisticated drug delivery systems like nanoparticles, show promise with respect lowering neuroinflammation greater specificity safety. Furthermore, developments biomarker discoveries neuroimaging improving our ability monitor responses, allowing more accurate personalized regimens. Preclinical clinical trial data demonstrate therapeutic potential tailored techniques. However, significant challenges remain, across BBB reducing off-target As research advances, creation personalized, cytokine-centered therapeutics has therapy landscape illnesses, giving patients hope better results higher quality life.
Language: Английский
Citations
1
Bioorganic Chemistry, Journal Year: 2025, Volume and Issue: 157, P. 108295 - 108295
Published: Feb. 21, 2025
Language: Английский
Citations
1
Journal of Enzyme Inhibition and Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 39(1)
Published: Feb. 16, 2024
Butyrylcholinesterase (BuChE) and neuroinflammation have recently emerged as promising therapeutic directions for Alzheimer's disease (AD). Herein, we synthesised 19 novel pyranone-carbamate derivatives evaluated their activities against cholinesterases neuroinflammation. The optimal compound 7p exhibited balanced BuChE inhibitory activity (eqBuChE IC50 = 4.68 nM; huBuChE 9.12 nM) anti-neuroinflammatory (NO inhibition 28.82% at 10 μM, comparable to hydrocortisone). Enzyme kinetic docking studies confirmed was a mix-type inhibitor. Additionally, displayed favourable drug-likeness properties in silico prediction, high BBB permeability the PAMPA-BBB assay. Compound had good safety vivo verified by an acute toxicity assay (LD50 > 1000 mg/kg). Most importantly, effectively mitigated cognitive memory impairments scopolamine-induced mouse model, showing effects Rivastigmine. Therefore, envisioned that could serve lead treating AD.
Language: Английский
Citations
6
Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 51(1)
Published: May 11, 2024
Language: Английский
Citations
6
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1207 - 1207
Published: Jan. 30, 2025
Nuclear receptors (NRs) are ligand-activated transcription factors that regulate a broad array of biological processes, including inflammation, lipid metabolism, cell proliferation, and apoptosis. Among the diverse family NRs, peroxisome proliferator-activated (PPARs), estrogen receptor (ER), liver X (LXR), farnesoid (FXR), retinoid (RXR), aryl hydrocarbon (AhR) have garnered significant attention for their roles in neurodegenerative diseases, particularly Alzheimer’s disease (AD). NRs influence pathophysiology AD through mechanisms such as modulation amyloid-beta (Aβ) deposition, regulation inflammatory pathways, improvement neuronal function. However, dual role progression, where some may exacerbate while others offer therapeutic potential, presents critical challenge application treatment. This review explores functional diversity highlighting involvement AD-related processes discussing prospects NR-targeting strategies. Furthermore, key challenges, necessity precise identification beneficial detailed structural analysis molecular dynamics simulations, further investigation NR AD, tau pathology autophagy, also discussed. Collectively, continued research is essential to clarify ultimately facilitating potential use diagnosis, prevention, treatment AD.
Language: Английский
Citations
0
NeuroMolecular Medicine, Journal Year: 2025, Volume and Issue: 27(1)
Published: March 7, 2025
Language: Английский
Citations
0
Cellular and Molecular Immunology, Journal Year: 2025, Volume and Issue: unknown
Published: March 13, 2025
Abstract Neuroinflammation plays an important role in the pathogenesis of various central nervous system (CNS) diseases. The NLRP3 inflammasome is intracellular multiprotein complex composed innate immune receptor NLRP3, adaptor protein ASC, and protease caspase-1. activation can induce pyroptosis release proinflammatory cytokines IL-1β IL-18, thus playing a inflammatory responses. Recent studies have revealed that activated brain to neuroinflammation, leading further neuronal damage functional impairment, contributes pathological process neurological diseases, such as multiple sclerosis, Parkinson’s disease, Alzheimer’s stroke. In this review, we summarize neuroinflammation course CNS diseases discuss potential approaches target for treatment
Language: Английский
Citations
0